Investigating the Structure-Activity Relationship of 1,2,4-Triazine G-Protein-Coupled Receptor 84 (GPR84) Antagonists

  • J Med Chem. 2022 Aug 25;65(16):11270-11290. doi: 10.1021/acs.jmedchem.2c00804.
Amit Mahindra  1 ,  Laura Jenkins  2 ,  Sara Marsango  2 ,  Mark Huggett  3  4 ,  Margaret Huggett  3  4 ,  Lindsay Robinson  3  4 ,  Jonathan Gillespie  3  4 ,  Muralikrishnan Rajamanickam  3  4 ,  Angus Morrison  3  4 ,  Stuart McElroy  3  4 ,  Irina G Tikhonova  5 ,  Graeme Milligan  2 ,  Andrew G Jamieson  1
Affiliations
  • 1. School of Chemistry, University of Glasgow, Joseph Black Building, University Avenue, Glasgow G12 8QQ, U.K.
  • 2. Centre for Translational Pharmacology, Institute of Molecular, Cell and Systems Biology, University of Glasgow, Davidson Building, Glasgow G12 8QQ, U.K.
  • 3. BioAscent Discovery Ltd., Newhouse, Lanarkshire ML1 5UH, U.K.
  • 4. European Screening Centre, University of Dundee, Newhouse, Lanarkshire ML1 5UH, U.K.
  • 5. School of Pharmacy, Medical Biology Centre, Queen's University Belfast, Belfast BT9 7BL, U.K.
PMID: 35948061 DOI: 10.1021/acs.jmedchem.2c00804
Abstract

G-protein-coupled receptor 84 (GPR84) is a proinflammatory orphan G-protein-coupled receptor implicated in several inflammatory and fibrotic diseases. Several agonist and antagonist ligands have been developed that target GPR84; however, a noncompetitive receptor blocker that was progressed to phase II clinical trials failed to demonstrate efficacy. New high-quality antagonists are required to investigate the pathophysiological role of GPR84 and to validate GPR84 as a therapeutic target. We previously reported the discovery of a novel triazine GPR84 competitive antagonist 1. Here, we describe an extensive structure-activity relationship (SAR) of antagonist 1 and also present in silico docking with supporting mutagenesis studies that reveals a potential binding pose for this type of orthosteric antagonist. Lead compound 42 is a potent GPR84 Antagonist with a favorable pharmacokinetic (PK) profile suitable for further drug development.

Products